517 related articles for article (PubMed ID: 33316402)
1. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
Jung SY; Kim MS; Kim MC; Choi SH; Chung JW; Choi ST
Clin Microbiol Infect; 2021 Apr; 27(4):611-617. PubMed ID: 33316402
[TBL] [Abstract][Full Text] [Related]
2. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.
Ferreira A; Oliveira-E-Silva A; Bettencourt P
J Med Virol; 2021 Feb; 93(2):755-759. PubMed ID: 32644224
[TBL] [Abstract][Full Text] [Related]
3. Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea.
Bae S; Ghang B; Kim YJ; Lim JS; Yun SC; Kim YG; Lee SO; Kim SH
Viruses; 2021 Feb; 13(2):. PubMed ID: 33672785
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.
Penn SK; Kao AH; Schott LL; Elliott JR; Toledo FG; Kuller L; Manzi S; Wasko MC
J Rheumatol; 2010 Jun; 37(6):1136-42. PubMed ID: 20436082
[TBL] [Abstract][Full Text] [Related]
5. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.
Walbi IA; Albarqi HA; Alghanim NS; Albadi MA; Al Maimouni HM; Alkahtani SA; Alshabi AM; Alali AS; Alqahtani F; Al-Najjar AH; Hazzazi MA; Alanazi DS; Sabei AA; Alsaweed OS; Alajra RK; Alqhtani H
J Int Med Res; 2022 Apr; 50(4):3000605221090363. PubMed ID: 35387504
[TBL] [Abstract][Full Text] [Related]
7. Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.
Pileggi GS; Ferreira GA; Reis APMG; Reis-Neto ET; Abreu MM; Albuquerque CP; Araújo NC; Bacchiega AB; Bianchi DV; Bica B; Bonfa ED; Borba EF; Brito DCSE; Duarte ÂLBP; Santo RCE; Fernandes PR; Guimarães MP; Gomes KWP; Kakehasi AM; Klumb EM; Lanna CCD; Marques CDL; Monticielo OA; Mota LMH; Munhoz GA; Paiva ES; Pereira HLA; Provenza JR; Ribeiro SLE; Junior LFR; Sampaio CSJC; Sampaio VS; Sato EI; Skare T; de Souza VA; Valim V; Lacerda MVG; Xavier RM; Pinheiro MM
Adv Rheumatol; 2021 Oct; 61(1):60. PubMed ID: 34620246
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy.
Salvarani C; Mancuso P; Gradellini F; Viani N; Pandolfi P; Reta M; Carrozzi G; Sandri G; Bajocchi G; Galli E; Muratore F; Boiardi L; Pipitone N; Cassone G; Croci S; Marata AM; Costantini M; Giorgi Rossi P
Arthritis Rheumatol; 2021 Jan; 73(1):48-52. PubMed ID: 32767527
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Pneumonia during Hydroxychloroquine Treatment of Rheumatoid Arthritis.
Gürsoy C; Tapan ÖO; Dogan E; Togan T; Demirbilek SG
J Coll Physicians Surg Pak; 2020 Oct; 30(10):168-170. PubMed ID: 33291197
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study.
Lo CH; Wei JC; Wang YH; Tsai CF; Chan KC; Li LC; Lo TH; Su CH
Front Immunol; 2021; 12():631869. PubMed ID: 33868251
[TBL] [Abstract][Full Text] [Related]
11. Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy.
Spila Alegiani S; Crisafulli S; Giorgi Rossi P; Mancuso P; Salvarani C; Atzeni F; Gini R; Kirchmayer U; Belleudi V; Kurotschka PK; Leoni O; Ludergnani M; Ferroni E; Baracco S; Massari M; Trifirò G;
Rheumatology (Oxford); 2021 Oct; 60(SI):SI25-SI36. PubMed ID: 33856453
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
Chen YM; Lin CH; Lan TH; Chen HH; Chang SN; Chen YH; Wang JS; Hung WT; Lan JL; Chen DY
Rheumatology (Oxford); 2015 Jul; 54(7):1244-9. PubMed ID: 25587177
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study.
Hung YM; Wang YH; Lin L; Wang PYP; Chiou JY; Wei JC
Int J Clin Pract; 2018 May; 72(5):e13095. PubMed ID: 29691971
[TBL] [Abstract][Full Text] [Related]
14. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.
Mavrikakis I; Sfikakis PP; Mavrikakis E; Rougas K; Nikolaou A; Kostopoulos C; Mavrikakis M
Ophthalmology; 2003 Jul; 110(7):1321-6. PubMed ID: 12867385
[TBL] [Abstract][Full Text] [Related]
15. Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine.
Tejada Cifuentes F; Lloret Callejo Á; Tirado Peláez MJ; Rubio Pulido O; Ruiz-Morote Aragón M; Fernández Urrusuno R; Muñoz Carreras MI; Méndez Esteban MI; Maestre Sánchez V; García Bonilla A; Paredero Dominguez JM; Arroyo Pineda V; Marco Tejón E; Romero Candel G; Fernández Marchante AI; Marco Del Rio J; Ortiz Martín T; López Sánchez P
Med Clin (Barc); 2021 Feb; 156(4):166-171. PubMed ID: 33308853
[TBL] [Abstract][Full Text] [Related]
16. Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study.
Pinheiro FO; Martins Carvalho M; Madureira P; Seabra Rato M; Macedo F; Costa L
Lupus; 2023 Mar; 32(3):388-393. PubMed ID: 36598483
[TBL] [Abstract][Full Text] [Related]
17. Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices.
Carlsson H; Hjorton K; Abujrais S; Rönnblom L; Åkerfeldt T; Kultima K
Arthritis Res Ther; 2020 Jun; 22(1):125. PubMed ID: 32475347
[TBL] [Abstract][Full Text] [Related]
18. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.
Rekedal LR; Massarotti E; Garg R; Bhatia R; Gleeson T; Lu B; Solomon DH
Arthritis Rheum; 2010 Dec; 62(12):3569-73. PubMed ID: 20722019
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
Dima A; Jurcut C; Arnaud L
Joint Bone Spine; 2021 May; 88(3):105143. PubMed ID: 33515791
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population.
Jorge A; McCormick N; Lu N; Zheng Y; Esdaile J; De Vera M; Choi H; Aviña-Zubieta JA
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1219-1223. PubMed ID: 32407570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
